Continuous Wireless Ultrasound to Monitor Fetal Health
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Wireless Ultrasound Device.
- Who it may be relevant to
- Registry conditions: Pregnant Woman With Single Pregnancy, Ultrasound Fetal Medicine. Basic parameters: from 18 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study is a single-center, prospective, and non-randomized feasibility study designed to evaluate the practicality, tolerability, and data quality of short-duration continuous fetal monitoring using a wireless bioadhesive ultrasound device. The study involves a single visit per participant and does not include any therapeutic intervention. Eligible participants will undergo placement of a wireless bioadhesive ultrasound (ABAUS) device on the maternal abdomen for a short-duration monitoring session. The device will acquire continuous or semi-continuous ultrasound data for a total of 10-30 minutes per participant, without altering standard clinical care. The study is observational and is intended to assess the technical feasibility of device placement, the stability of the coupling during routine maternal movement, image quality over time, and the ability to monitor fetal motion, heart rate, and uterine activity using the investigational device under controlled yet realistic clinical conditions. The study is non-interventional. No diagnostic or therapeutic decisions will be made based on the ultrasound data collected as part of this research protocol, and all standard prenatal care will proceed independently of participation in this study.
Interventions
- Device Wireless Ultrasound Device
Participants will undergo placement of the investigational wireless bio-adhesive ultrasound (ABAUS) device on the maternal abdomen. This device constitutes the sole study-related exposure. The device will be externally applied to intact abdominal skin using a skin-safe bio-adhesive and used to acquire continuous or semi-continuous ultrasound data for approximately 10-30 minutes.
Primary outcome measures
- Successful continuous abdominal imaging over a defined monitoring interval [Time frame: 10-30 minutes]
- Number of skin adverse events [Time frame: 30 - 60 minutes]
Eligibility criteria
Inclusion criteria
- Pregnant individual 18 years or older
- Singleton uterine pregnancy
- Gestational age 20 to 39 gestational weeks
- Able to provide written informed consent
- Willing to go an single visit lasting 45 minutes - 1 hour including device placement, monitoring and removal
- Willing to permit placement of the wireless bioadhesive ultrasound device on their abdomen for approximately 10-30 minutes
Exclusion criteria
- Multiple gestation
- Maternal abdominal skin condition at the potential site of attachment, such as rash, open wound, etc., preventing placement
- Known allergy or hypersensitivity to adhesive material or hydrogel products
- Need for urgent clinical management/triage
- BMI > 35, as the signal quality could be impacted by BMI and not the device specifically
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-only
Study locations
United States · 1 center
- Boston Children's Hospital — Boston
Identifiers
NCT: NCT07676474 · IRB-P00054387